Hadi, Marym Mohammad; Nesbitt, Heather; Masood, Hamzah; Sciscione, Fabiola; Patel, Shiv; Ramesh, Bala S.; Emberton, Mark; Callan, John F.; MacRobert, Alexander; McHale, Anthony P.; Nomikou, Nikolitsa published their research in Journal of Controlled Release in 2021. The article was titled 《Investigating the performance of a novel pH and cathepsin B sensitive, stimulus-responsive nanoparticle for optimized sonodynamic therapy in prostate cancer》.Reference of 1,3-Diphenylisobenzofuran The article contains the following contents:
Nano-formulations that are responsive to tumor-related and externally-applied stimuli can offer improved, site-specific antitumor effects, and can improve the efficacy of conventional therapeutic agents. Here, we describe the performance of a novel stimulus-responsive nanoparticulate platform for the targeted treatment of prostate cancer using sonodynamic therapy (SDT). The nanoparticles were prepared by self-assembly of poly(L-glutamic acid-L-tyrosine) co-polymer with hematoporphyrin. The nanoparticulate formulation was characterized with respect to particle size, morphol., surface charge and singlet oxygen production during ultrasound exposure. The response of the formulation to the presence of cathepsin B, a proteolytic enzyme that is overexpressed and secreted in the tumor microenvironment of many solid tumors, was assessed. Our results showed that digestion with cathepsin B led to nanoparticle size reduction In the absence of ultrasound, the formulation exhibited greater toxicity at acidic pH than at physiol. pH, using the human prostate cells lines LNCaP and PC3 as targets. Nanoparticle cellular uptake was enhanced at acidic pH – a condition that was also associated with greater cathepsin B production Nanoparticles exhibited enhanced ultrasound-induced cytotoxicity against both prostate cancer cell lines. Subsequent proof-of-concept in vivo studies demonstrated that, when ectopic human xenograft LNCaP tumors in SCID mice were treated with SDT using the systemically-administered nanoparticulate formulation at a single dose, tumor volumes decreased by up to 64% within 24 h. No adverse effects were observed in the nanoparticle-treated mice and their body weight remained stable. The potential of this novel formulation to deliver safe and effective treatment of prostate cancer is discussed. The results came from multiple reactions, including the reaction of 1,3-Diphenylisobenzofuran(cas: 5471-63-6Reference of 1,3-Diphenylisobenzofuran)
1,3-Diphenylisobenzofuran(cas: 5471-63-6) can be used as a fluorescent probe for detection of superoxide anion radical (O2−) inside the membrane lipid layer by DPBF fluorescence quenching method. 1,3-Diphenylisobenzofuran(DPBF) can be used to study the single crystal molecular structure and solution photophysical properties of DPBF.Reference of 1,3-Diphenylisobenzofuran
Referemce:
Benzofuran – Wikipedia,
Benzofuran | C8H6O – PubChem